Browse Studies — Arctuva

Phase 3

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Ev…

Transthyretin Amyloidosis With Cardiomyopathy

Estimated

~$10 – $8,750

Alnylam PharmaceuticalsNCT07052903

Post-Authorisation Safety Study: A Cohort Event Monitoring Study to Characterise the Use of Eplontersen in Patients With Prior Liver Transplant and Pre-existing Severe Hepatic Impairment and to Assess Long-term Safety Among All New Users of Eplontersen (sTTRing)

The aim of this observational cohort study is to characterise use of eplontersen in patients with prior liver transplant or with pre-existing severe hepatic im…

Transthyretin AmyloidosisTransthyretin Amyloidosis With CardiomyopathyTransthyretin Amyloidosis With Polyneuropathy

Estimated

~$10 – $1,125

AstraZenecaNCT07654855

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-C…

Transthyretin Amyloidosis With Cardiomyopathy

Estimated

~$10 – $1,050

Alnylam PharmaceuticalsNCT07358078